Lauren Chazal has a strong command of the clinical trials industry from a site operations, business development and financial management perspective. She began her career in clinical trial operations with a privately-held multi-site clinical research organization. Since 2012, she has held a pivotal role in business development, M&A and relationship management for clinical research sites globally. Lauren has in-depth knowledge of the complex interactions between clinical research centers, CROs and sponsors combined with a keen understanding of the importance of access to high quality trial sites and patient recruitment solutions.
Lauren graduated from Lehigh University with a dual degree in Finance and Marketing and from the University of Florida with a Master’s in Business Administration (MBA). Lauren is a current member and SW Region Treasurer of Healthcare Businesswomen’s Association (HBA) and board member of International Women’s Forum (IWF) Arizona Chapter as well as a four-time marathon runner.

Ryan Cady brings over a decade of experience to the clinical research industry, with a career that began in 2013 at Clinvest Research in Springfield, MO. Stepping into leadership after his father’s retirement in 2016, Ryan successfully led the company until its integration with Headlands Research in May 2023. His academic background is solidly rooted in the sciences, holding an undergraduate degree in Neurobiology from the University of Wisconsin-Madison and a master’s degree in Biology from Missouri State University. Ryan has a passion for both Sponsor relationship-building and small biotech CRO interactions with a focus in Metabolic/Endocrine, Pain and Rheumatology.

Beyond his professional pursuits, Ryan has a passion for exploring the world through culinary adventures, gardening, cooking, and bee-keeping.

McKenzie Lang possesses a deep understanding of clinical research through her years of experience representing sites within the US and internationally. McKenzie understands the importance of clinical trials and how site networks play an integral role in expediting the drug development process. McKenzie has worked for several site organizations, including Bioclinica and Wake Research, over the past decade and understands the importance of strong collaborative Industry relationships that benefit patients. McKenzie is located in Raleigh, NC.

McKenzie graduated from East Carolina University with a B.S. in Biology.

Hailing from Buenos Aires, Argentina, Mauro brings over 8 years’ experience leading clinical research sites. He has been responsible for business development, operations, accounting, finance, marketing, advertising, recruitment, QA, start-up, and regulatory teams. Prior to joining Headlands, Mauro served as the Director of Operations for a multi-site clinical research group, which grew ten-fold during his tenure. His passion lies in making connections – trials to patients, Sponsors/CROs to sites, CROs to Sponsors, and new friends to old.

Mauro graduated from the University of California San Diego with a degree in Human Development and received his MBA from Loyola University in New Orleans. He loves to golf, play basketball, and watch the Mardi Gras floats parade down St. Charles Avenue.

Jordan began his clinical research career in 2011, bringing his love for people and medicine. Prior to joining Headlands, Jordan served as Vice President of Clinical Operations at Peninsula Research Associates, overseeing daily clinical operations along with contributing to business development and negotiation of all trial budgets. His background in Physiology combined with his MBA allowed Jordan to grasp clinical research from all angles and help grow PRA during his tenure.

Jordan received his Bachelor of Science degree in Physiology from the University of Arizona and his Master of Business Administration from the Graziadio School of Business and Management at Pepperdine University. Outside of clinical research, Jordan enjoys skiing, golfing, and spending time with his young family, his wife, and two boys Liam and Riley.

From creating research programs with naïve practices to assisting multi-specialty site networks reach their goals, Tori has seen and done it all. Since 2016, Tori has had a hand in a full spectrum of activities aimed towards creating thriving research programs. For many years, she focused on the importance of cultivating and maintaining relationships—with accounts, with Sponsor/CRO partners, and bridging the gap between those two parties. Prior to joining Headlands, Tori held various Business Development, Account Management, and Operational roles at ClinEdge, giving her a unique understanding from multiple perspectives of what it takes to stand out and be successful.

As a New Orleans native, Tori attended Loyola University New Orleans earning a degree in Social Sciences with a minor in Women’s Studies. In her off time, you will find her kayaking the bayou, attending the myriad of festivals the city has to offer, and hunting down the best food pop-ups with her moody rescue dog, Boudreaux, in tow.

Kayla Kramschuster joined the Headlands Research team as the Global Feasibility Analyst. Kayla has previous work experience in the healthcare realm and Clinical Trials research in particular. Most recently as a Clinical Trials Data Coordinator for the Precision Medicine Team at the University of Wisconsin’s Carbone Cancer Center. Kayla will be working closely with the Business Development team to deliver robust feasibilities to Headlands sites within defined scope and timelines.

Kayla graduated from the University of Wisconsin with a B.S degree in Community and Environmental Sociology and Environmental Studies and currently lives in Madison, Wisconsin with her dog Brady.

Cathy Collins brings over 29 years of clinical trial experience to the Headlands team. Her background includes extensive de novo site development (Clinical Studies, LTD and Meridien) as well as site PE backed acquisition/integration (Protocare trials). She is the former owner/CEO of Meridien Research a 5 site, dedicated site organization and Insearch, a business development provider which were both sold to private equity (2012). Prior to joining the Headlands team, Cathy has served as the President and CEO of Clinical Consulting Solutions (CCS), a full-service clinical trials consulting firm providing consulting services spanning new site start-up, therapeutic development, financial/process improvement, and pre-acquisition PE due diligence (2014).

Cathy hold Bachelors and Master’s degrees in nursing and is a 2015 graduate of the Harvard Business School OPM program. She serves on a number of boards in her community including the Bank of Tampa and University of Tampa.

Anuv Ratan joined KKR in 2017 and is a member of the Health Care industry team. At KKR, he has been involved with investments in Gamma Biosciences, Impel Neuropharma, Headlands Research, BrightSpring Pharmerica, Global Medical Response, Ajax Health, and Aimmune Therapeutics. He is currently a member of the board of directors of Gamma Biosciences, Blue Sprig Pediatrics, and Headlands Research. Prior to joining KKR, Mr. Ratan was with FFL Partners, where he was involved in a number of health care transactions. Mr. Ratan began his career at The Blackstone Group. He holds an A.B., with honors, in Neurobiology from Harvard University.

Ali J. Satvat joined KKR in 2012 and is a Member of KKR on the Health Care industry team within KKR’s Americas Private Equity platform. He leads KKR’s Health Care Strategic Growth investing efforts, sits on the Health Care Strategic Growth Investment Committee and is Chairman of the Health Care Strategic Growth Portfolio Management Committee. He currently serves on the boards of directors of AcuFocus, Arbor Pharmaceuticals, Blue Sprig Pediatrics, BridgeBio Pharma, Clarify Health Solutions, Cohera Medical, Coherus BioSciences, Eidos Therapeutics, Headlands Research, Impel NeuroPharma, Slayback Pharma, and Trilogy MedWaste and has been involved in KKR’s investments in Ajax Health, PRA Health Sciences, and Spirox. Previously, he held various positions with Apax Partners, Johnson & Johnson Development Corporation, Audax Group, and The Blackstone Group. Mr. Satvat holds an A.B., magna cum laude, in History and Science from Harvard College and an M.B.A. in Health Care Management and Entrepreneurial Management from the Wharton School of the University of Pennsylvania. He is a member of the board of directors of the Healthcare Private Equity Association.

Dr. Sharon Cohen is a behavioural neurologist known for her excellence in patient care, teaching, and clinical research. She completed her neurology residency and behavioural neurology fellowship at the University of Toronto. She is the medical director and site principal investigator of Toronto Memory Program, a community-based medical facility which she established in 1996 for the purpose of enhancing diagnosis, care, and therapeutic options for individuals with or at risk for Alzheimer’s disease and related disorders. Under her guidance, Toronto Memory Program’s multidisciplinary team has grown to a staff of 30 individuals. Its memory clinic and research site are among the most active in Canada.

Dr. Cohen has over 28 years of experience in clinical research and has been a site PI for over 100 pharmacological trials. She has participated in acute stroke trials as well as trials in FTD, PDD, DLB, HD, vascular dementia, and Alzheimer’s disease, the latter being her primary focus. Her site has been credited as a “go to” centre for Alzheimer’s trials and has been awarded for superior performance and quality in clinical research.

Dr. Cohen represents Canada on international advisory boards and steering committees and is a consultant to a wide range of stakeholders in dementia including government organizations and patient advocacy groups. She is a frequent lecturer and contributes to media events including those on medical ethics. She is known for her advocacy of individuals with neurodegenerative diseases.

Despite holding academic and hospital appointments, Dr. Cohen chooses to practice in the community, in keeping with her belief that dementia care and clinical research are best offered in the real world setting.

Dr. Vishaal Mehra attended Texas A&M Health Science Center for his Medical Degree, and then completed his residency in Psychiatry at the University of California, San Diego. He began his career as an Investigator in clinical research in 2007.

As a Principal Investigator, Dr. Mehra worked in a variety of psychiatry and neurology therapeutic areas. He also worked closely with Sponsors and CROs to promote study-wide trial success, acting as a liaison for other Principal Investigators and the sponsor for several trials. Dr. Vishaal Mehra founded Artemis Institute for Clinical Research in 2008.

Dr. Goldstein was born and raised in New York City. He graduated Colgate University, receiving a B.A. degree with a major in Biophysics. He obtained his MD degree from Emory University School of Medicine in Atlanta. Upon graduation, he completed residencies in both Internal Medicine (College of Medicine and Dentistry of New Jersey/Robert Wood Johnson) and Neurology (Stanford University). He is board certified in both Internal Medicine and Neurology. After relocating to South Florida, he joined a busy clinical neurology practice which he helped grow to 6 Neurologists.

Dr. Goldstein began participating in clinical trials in the late 1990’s. To date, he has participated in over 80 clinical trials, being the Principal Investigator 70 times. Most of these trials have been conducted through JEM Research Institute, of which he is a founding member and the CEO. Under his guidance, JEM has grown into a substantial clinical research site currently employing 26 people, and conducting over 20 active trials at any one time, many of which deal with progressive cognitive decline.

As a clinical neurologist, Dr. Goldstein serves as an Affiliated Assistant Clinical Professor of Neurology at the University of Miami. As a researcher, he is a Certified Principal Investigator as well as a Fellow of the Academy of Physicians in Clinical Research.

Dr. Goldstein has served on the board of directors of the Medical Specialists of The Palm Beaches, the largest multispecialty medical group in Palm Beach County. He has also been a member of the executive committee as well as chairman of the credentials committee at JFK Hospital in Atlantis. He has been both the Chief of the Division of Neurology and the Director of the Comprehensive Stroke Center at JFK.